The biotech Spark Therapeutics needed a way to measure improvements to a patient's quality of life when testing a new treatment for a rare eye disorder. So Spark created a maze-like course, which included simulated obstacles like holes and grass, for use in key research. We spoke with Dan Chung, the clinical ophthalmic lead at Spark, about the company's efforts to do that in a rigorous and standardized way. Spark's treatment was approved in the US in late 2017. The one-time therapy is called Luxturna and has a list price of $850,000. And Spark agreed to be acquired by... [Read More]

Even if John Roberts ultimately upholds Obamacare yet again, that will take time, and an appeals-court verdict against the law would give Democrats lots of ammunition to use on Republicans. [Read More]

WeWork's parent company is considering a valuation of around $20 billion for its IPO, according to reports from The Wall Street Journal and Bloomberg. That would amount to roughly half of WeWork's $47 billion valuation. Softbank, one of the company's biggest investors, may infuse more capital in WeWork. A further Softbank investment could allow WeWork to delay its IPO until 2020, the Journal reported. Visit Business Insider's homepage for more stories. WeWork's parent company the We Company is eyeing a valuation of around $20 billion in its initial public offering, according to reports from Bloomberg and... [Read More]

British Prime Minister Boris Johnson's plan to kick off what is in effect an election campaign casting parliament as the enemy of Brexit was overshadowed on Thursday when his younger brother quit the government, citing the national interest. [Read More]

By Daniel Gallan, for CNN The son of the former Brazil captain and two-time World Cup winner Cafu has died of a suspected heart attack at the age of 30 while playing football near his family... [Read More]